Key result
Novel cryoballoon ablation achieves 100% PVI with no procedural or device-related serious adverse events.
Why the study?
Current cryoballoon PVI limitations include incomplete vein occlusion from balloon rigidity and inconsistent electrogram recording, so investigators evaluated the acute safety and performance of a novel cryoballoon system.
Does a novel cryoballoon ablation system safely and effectively achieve pulmonary vein isolation in patients with paroxysmal atrial fibrillation?
Population
30 patients with paroxysmal AF enrolled at two centres
Comparison
Novel cryoballoon ablation system
Design
Two-centre study
Follow-up
30 days post-procedure, with 1-year follow-up in a subset
Authors
Loading...
Supports feasibility of novel cryoballoon for PVI; leaves open safety, efficacy, and generalizability pending larger randomized trials.
Observational (n=30)
Yes
Does a novel cryoballoon ablation system safely and effectively achieve pulmonary vein isolation in patients with paroxysmal atrial fibrillation?
The novel cryoballoon ablation system demonstrated acute safety and 100% acute pulmonary vein isolation efficacy in an initial cohort of patients with paroxysmal atrial fibrillation.
Anić et al. (2021) conducted an observational in paroxysmal atrial fibrillation (n=30). Novel cryoballoon ablation system was evaluated on Acute safety and vein isolation. A novel cryoballoon ablation system achieved pulmonary vein isolation in 100% of veins (120/120) with no procedural or device-related serious adverse events at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: